[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardio-renal-metabolic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardio-renal-metabolic-syndrome":52},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100634709","effectiveness-of-laser-acupuncture-in-improving-arterial-stiffness-among-patients-with-cardiorenal-metabolic-syndrome-100634709",false,"NCT07543211","Effectiveness of Laser Acupuncture in Improving Arterial Stiffness Among Patients With Cardiorenal Metabolic Syndrome","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Diagnosed with at least two conditions related to cardio-renal-metabolic syndrome (e.g., hypertension, diabetes mellitus, chronic kidney disease, or dyslipidemia)\n3. Receiving routine laser acupuncture treatment in a clinical setting\n4. Able to understand the study procedures and provide informed consent\n\nExclusion Criteria:\n\n1. Presence of acute cardiovascular events (e.g., acute myocardial infarction, stroke)\n2. Acute kidney injury\n3. Presence of medical devices or conditions that contraindicate the use of laser acupuncture at the treatment site (e.g., arteriovenous shunt)\n4. Unable to complete the study procedures or follow-up assessments","ALL","18 Years",{"count":18,"type":19},35,"ESTIMATED","OBSERVATIONAL","Background: Cardio-renal metabolic syndrome (CRMS) is a vicious cycle of cardiac, renal, and metabolic disease, representing a high-risk for atherosclerosis. Laser acupuncture modulates vascular inflammation and improves endothelial function via low-level laser therapy (LLLT, \\\u003C500mW) at acupoints or musculoskeletal pain sites. Few studies have focused on CRMS populations. This study evaluates laser acupuncture effects on arterial stiffness in CRMS.\n\nPurpose: To assess the effects of improvement of laser acupuncture in patients with CRMS, and to evaluate its feasibility as supportive therapy.\n\nMethods: A single-group pre-post design is used. Participants are patients with CRMS receiving laser acupuncture at a Chinese medicine clinic in Taiwan. CRMS is interrelated by cardiac, renal, and metabolic disease. Inclusion criteria require diagnosis in ≥2 of 3 systems (cardiovascular, renal, or metabolic; n = 35). Laser acupuncture will be applied to bilateral BL40 for 12 weeks (1-3 sessions\u002Fweek, 60mins\u002Fsession). Pulse wave velocity(PWV) measured by Omron HBP- 8000 as the primary outcome for arterial stiffness. Paired t-tests and GEE will be used for analysis.\n\nExpected Results: PWV is expected to show significant improvement after intervention.",[23,24,25,26],"Hypertension","Diabetes Mellitus","Chronic Kidney Disease","Cardio-Renal-Metabolic Syndrome","NOT_YET_RECRUITING","2026-04-15",{"date":30,"type":31},"2026-04-21","ACTUAL",{"date":33,"type":19},"2026-05",{"date":35,"type":19},"2026-10",{"name":37,"class":38},"National Yang Ming Chiao Tung University","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100622223","cardio-reno--hepato--metabolic-disease-in-chronic-heart-failure-carmen-chf-100622223","NCT07380828","CArdio-Reno- Hepato -MEtabolic Disease iN Chronic Heart Failure (CARMEN-CHF)","Multicenter Observational Prospective Study of Cardio-reno- Hepato -Metabolic Disease in Chronic Heart Failure","CARMEN-CHF","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. A diagnosis that satisfies one of the following criteria:\n\n   * At least one of the following:\n\nLVEF \\\u003C50%, LV longitudinal systolic strain (GLS) \\\u003C18%, NT-proBNP \\>125 pg\u002FmL in sinus rhythm or 365 in AF\u002FAT, E\u002Fé \\>9 at rest by tissue Doppler, Indexed left ventricular volume (ILV) \\>34 mL\u002Fm2 in sinus rhythm or 40 mL\u002Fm2 in AF\u002FAT, Tricuspid regurgitation (TR) velocity \\>2.8 m\u002Fs or pulmonary artery systolic pressure (PASP) \\>35 mmHg. at rest, Left ventricular myocardial mass index (LVMI) \\>115\u002F95 g\u002Fm2 in men\u002Fwomen and relative wall thickness (RWT) \\>0.42, in the absence of symptoms and\u002For signs of current or past CHF, which corresponds to \"pre-CHF\" in accordance with the 2024 clinical guidelines.\n\nor\n\n* LVEF \\\u003C50% and the presence of symptoms and\u002For signs of current or past CHF or\n* LVEF ≥50% and the presence of symptoms and\u002For signs of current or past CHF, as well as at least one of the following (A, B, C) criteria:\n\nA. Presence of one of the signs of structural and\u002For functional heart disorders consistent with the presence of diastolic dysfunction \u002F elevated left ventricular filling pressure:\n\n1. . NT-proBNP level \\>200 pg\u002FmL in sinus rhythm or \\>600 pg\u002FmL in AF\u002FAT,\n2. . E\u002Fé \\>13 at rest by tissue Doppler,\n3. . 13 ≥E\u002Fé \\>9 + left atrial dilation (LAD) \\>34 ml\u002Fm2 in sinus rhythm or \\>40 ml\u002Fm2 in AF\u002FAT,\n4. . 13 ≥E\u002Fé \\>9 + TR velocity \\>2.8 m\u002Fs or PASP \\>35 mmHg at rest,\n5. . 13 ≥E\u002Fé \\>9 + presence of left ventricular hypertrophy, defined as LVMI \\>115 g\u002Fm2 in men and \\>95 g\u002Fm2 in women, WCT \\>0.42, OR B. Presence of 7-9 points on the H2FPEF scale; OR C. Positive diastolic stress test result confirming increased LV filling pressure (E\u002Fe'≥15, TR velocity \\>3.4 m\u002Fs) 3. No intravenous therapy with diuretics, nitrates, vasopressors, or inotropes within 24 hours prior to inclusion; 4. Availability of results of all of the following tests, performed no earlier than in the previous 6 months prior to inclusion in the study:\n\n\\[1\\] Complete blood count with hemoglobin and platelet levels, \\[2\\] Blood chemistry with total bilirubin, ALT, and AST levels, \\[3\\] Serum uric acid and creatinine levels, with glomerular filtration rate (eGFR) calculation using the 2021 CKD-EPI formula, \\[4\\] Fasting glucose and HbA1c, and, if the diagnosis is uncertain, an oral glucose tolerance test, \\[5\\] Ultrasound of the carotid and\u002For femoral arteries (only in patients with no prior history of atherosclerotic cardiovascular disease), \\[6\\] Urine test for CKD markers - at least one of the following: daily albuminuria (mg\u002Fday) and\u002For albumin\u002Fcreatinine ratio in a single urine portion (mg\u002Fg or mg\u002Fmmol) and\u002For daily proteinuria (g\u002Fday) and\u002For protein\u002Fcreatinine ratio in a single urine portion (mg\u002Fg or mg\u002Fmmol). -\n\nExclusion Criteria:\n\n* 1\\. Current participation in a randomized clinical trial; 2. Confirmed or suspected diagnosis of an alternative or comorbid condition that, in the opinion of the investigator, may explain the patient's symptoms and signs of CHF; 3. History of heart transplantation, combined congenital heart disease, or the presence of a mechanical circulatory support device; 4. Cardiac tamponade; 5. Pregnancy and lactation, planning a pregnancy in the next 24 months; 6. Acute cerebrovascular accident, transient ischemic attack, acute coronary syndrome, or coronary revascularization within less than 30 days prior to or on the day of study inclusion; 7. Acute dysfunction or failure of one or more internal organs within 3 months prior to or on the day of inclusion; 8. Any cardiac surgery performed within 3 months prior to enrollment or planned within the next 6 months, including implantation of intracardiac devices, ablation for cardiac arrhythmias, or correction of valvular pathology; 9. Severe cognitive impairment or other conditions that, in the opinion of the investigator, prevent the patient from understanding the program, providing informed consent, or interfere with participation in the study; 10. Active cancer; 11. Verified cardiac amyloidosis or other infiltrative cardiomyopathy (hemochromatosis, Fabry disease, Gaucher disease); 12. Verified hereditary cardiomyopathy; 13. Heart disease due to reversible causes (e.g., Takotsubo syndrome).",{"count":48,"type":19},3000,"Study aims to investigate the incidence, associations and prognostic value of CRGM and its components: chronic kidney disease, type 2 diabetes, atherosclerotic cardiovascular diseases, and non-alcoholic fatty liver disease in patients with different phenotypes and severity of clinical manifestations of CHF.",[51,52],"Heart Failure","Cardio-renal-metabolic Syndrome",[54,55,56,57],"obesity","atherosclerosis","type 2 diabetes mellitus","heart failure","2026-01-24",{"date":60,"type":31},"2026-02-02",{"date":62,"type":19},"2026-02",{"date":64,"type":19},"2029-05",{"name":66,"class":38},"Russian Scientific Medical Society of Therapists"]